Loading... (0%)

News + Events

news

3-V Biosciences Completes $20 Million Series C Financing

21 June 2013

Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V’s lead oncology candidate into a Phase 1 clinical trial…

3­‐V Biosciences presented two publications at AASLD

03 December 2012

3­‐V Biosciences presented two publications at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) held November 9‐13 in Boston, Massachusetts. BACKGROUND: Optimized new therapies for HCV are needed that have pan genotypic activity and a high barrier to viral resistance. To meet these challenges, 3-V Biosciences…

3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012

12 November 2012

Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of…

3­‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012

01 October 2012

Menlo Park, California, October 1, 2012. 3­‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9‐13 in Boston, Massachusetts. 3‐V Biosciences is discovering and developing oral antiviral therapeutics designed to…

3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program

09 July 2012

Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV). “The continued support of the company’s investors for the host-factor vision reflects both the success of the team thus…

3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology

29 June 2012

Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology.  Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. “With our…